Aarons, L. and Gupta, S. K
A Mixed-Effects Modelling Approach To The Analysis Of Verapamil-GITS Blood Pressure Data
|
N. Bleyzac1,2 , F. Vial1 , B. Allard-Latour1 , J. Mouret1 , R W. Jelliffe2 , P. H. Maire1,2
Contribution Of Nonparametric Population Pharmacokinetic Software To The Determination Of Diurnal Variations Of Drug Pharmacokinetic Parameters
|
Dubruc C, *Mesnil F, Thenot JP, *Mentré F.
Population Pharmacokinetic Analysis Of Mizolastine In Healthy Young Volunteers And Allergic Patients Using NONMEM
|
M.-E. Ebelin1, F. Mentré2, P. Burtin1, R. Laplanche3 1
Pharmacokinetic Population Analysis Of SDZ ENA 713 And Its Metabolite In Patients; Relationships With Efficacy, Safety And Tolerability
|
Frey, N., Laveille, C., Kiefer, Ph., Laudignon, N. And Jochemsen, R.
Population Pharmacokinetics/Pharmacodynamics Of A New Formulation Of Gliclazide In 224 Type 2 Diabetics.
|
Garcia MJ, Santos Buelga D, Otero MJ, Serrano J, Blanco B, Dominguez-Gil A
Population Pharmacokinetics: Effect Of Polytherapy On Valproic Acid Clearance
|
Niclas Jonsson and Mats Karlsson
Covariate Model Building In Population Analysis Using A Bootstrap Resampling Procedure
|
Khan, A.Z.1, Pitsiu, M.1, Aarons, L.A2, Parivar, K.3, Widman, M3
Population Pharmacokinetic Analysis Of Eltanolone
|
Per Larsson, Eva Weibull, Astra Draco AB, Lund, Sweden, Søren Pedersen, Lone Agertoft,
Estimation Of Bioavailability Using A Semi-Simultaneous Design
|
Laveille, C., Frey, N., Lerebours, G., Resplandy, G. And Jochemsen, R
Population Pharmacokinetics-Pharmacodynamics Of A New Specific Bradycardic Agent (S 16257) And Its Metabolite (S 18982) Evaluation Of The Drug/Metabolite Potency Ratio
|
Modamio P, Jansat JM, Lastra CF, Mariño EL
Change In The Analytical Error Function Depending On The Calibration Curve Range: Implications For Pharmacokinetic Parameter Estimation Of Carebastine.
|
V. Piotrovskij, V. Van de Velde, A. Van Pee
Population Analysis Of Lubeluzole Pharmacokinetics In Healthy Volunteers And Patients With Ischaemic Stroke
|
M. du Preez1, J. Botha1, and L. McFadyen2
A Count Model For Analysing PK/PD Data For Theophylline In Neonatal Apnoea
|
Silvia Romano, A.C. Falcao Mª. del Mar Fdz. de Gatta, Mª. Victoria Calvo, Mª. Eugenia Méndez, Alfonso Domínguez-Gil, José M. Lanao
Pharmacokinetics of amikacin in intensive care unit patients: population analysis.
|
M. Rosario1,4, C.A. Sharp2, D.I. Jodrell3, A.H. Thomson1
Population Pharmacokinetics Of Gentamicin In Oncology Patients
|
A. Rostami-Hodjegan, GT Tucker
On estimating half-life using population pharmacokinetics
|
Lee P. Topping and Dr. Nicholas T. Longford
An Alternative Definition Of Individual Bioequivalence
|
Tranchand B1, Pobel C2, Ardiet CJ1, Parola JN2, Ménard G2
Pharmacokinetic-Dynamic Modelling Of Neutropenic Effect Of Melphalan Using NONMEM Associated With A Cubic Spline Function
|
Iñaki F. Trocóniz1,2, Tarja Naukkarinen 3,4, Mats O. Karlsson4
Population Pharmacodynamic Modelling of Levodopa in Parkinsonian Patients Receiving the COMT Inhibitor Entacapone
|
